{"id":"glucagon-nasal-powder","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glucagon is a peptide hormone that activates glucagon receptors on liver cells, triggering the breakdown of stored glycogen into glucose and promoting the synthesis of new glucose from precursors. This nasal powder formulation allows rapid non-injectable delivery for emergency treatment of severe hypoglycemia. The intranasal route provides faster absorption and easier administration compared to traditional intramuscular injection in acute settings.","oneSentence":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:05.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe hypoglycemia in patients with diabetes"}]},"trialDetails":[{"nctId":"NCT04992312","phase":"PHASE1","title":"A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-03-24","conditions":"Type 1 Diabetes","enrollment":7},{"nctId":"NCT02171130","phase":"PHASE3","title":"Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2014-05","conditions":"Hypoglycemia, Diabetes Mellitus, Drug-Specific Antibodies","enrollment":129},{"nctId":"NCT03421379","phase":"PHASE3","title":"A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-02-21","conditions":"Diabetes Mellitus","enrollment":75},{"nctId":"NCT01556594","phase":"PHASE2","title":"Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-03","conditions":"Hypoglycemia","enrollment":18},{"nctId":"NCT02402933","phase":"PHASE3","title":"Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-03","conditions":"Hypoglycemia, Diabetes Mellitus","enrollment":26}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"RENAL FAILURE"}],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY900018"],"phase":"phase_3","status":"active","brandName":"Glucagon Nasal Powder","genericName":"Glucagon Nasal Powder","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glucagon binds to glucagon receptors on hepatic cells to stimulate glycogenolysis and gluconeogenesis, rapidly raising blood glucose levels. Used for Severe hypoglycemia in patients with diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}